Kadmon Announces Oral Presentation on KD025 in cGVHD at EHA Congress

NEW YORK–(BUSINESS WIRE)–Kadmon Holdings, Inc. (NYSE:KDMN) today announced that additional data
from its ongoing Phase 2 clinical trial of KD025 in chronic
graft-versus-host disease (cGVHD) will be highlighted in an oral
presentation at the 23rd Congress of the European Hematology
Association (EHA), to be held June 14-17, 2018 in Stockholm, Sweden.

Details for the presentation are as follows:

EHA Presentation Details
& Time:
Saturday, June 16, 4:30 – 4:45 p.m. CEST
KD025-208: A Phase 2 Open-Label Trial of KD025 for Steroid-Dependent
Chronic Graft-Versus-Host Disease (cGVHD)

About KD025
KD025 is a selective oral inhibitor of
Rho-associated coiled-coil kinase 2 (ROCK2), a signaling pathway that
mediates cell movement, shape, differentiation and function and is
dysregulated in many chronic diseases, including cGVHD. In October 2017,
KD025 received orphan drug designation from the U.S. Food and Drug
Administration (FDA) for cGVHD. In April 2018, based on FDA guidance,
Kadmon announced a planned open-label, pivotal study of KD025 in cGVHD.

About cGVHD
cGVHD is a common and often fatal complication
following hematopoietic stem cell transplantation, a procedure that is
often used to treat patients with cancers such as myeloma or leukemia.
With cGVHD, transplanted immune cells (graft) attack the patient’s cells
(host), leading to inflammation and fibrosis in multiple tissues,
including skin, mouth, eye, joints, liver, lung, esophagus and GI tract.

About Kadmon Holdings, Inc.
Kadmon Holdings, Inc. is a fully
integrated biopharmaceutical company developing innovative products for
significant unmet medical needs. Our product pipeline is focused on
inflammatory and fibrotic diseases.

Forward Looking Statements
This press release contains
forward-looking statements. Such statements may be preceded by the words
“may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,”
“intends,” “targets,” “projects,” “contemplates,” “believes,”
“estimates,” “predicts,” “potential” or “continue” or the negative of
these terms or other similar expressions. Forward-looking statements
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements. We
believe that these factors include, but are not limited to, (i) the
initiation, timing, progress and results of our preclinical studies and
clinical trials, and our research and development programs; (ii) our
ability to advance product candidates into, and successfully complete,
clinical trials; (iii) our reliance on the success of our product
candidates; (iv) the timing or likelihood of regulatory filings and
approvals; (v) our ability to expand our sales and marketing
capabilities; (vi) the commercialization of our product candidates, if
approved; (vii) the pricing and reimbursement of our product candidates,
if approved; (viii) the implementation of our business model, strategic
plans for our business, product candidates and technology; (ix) the
scope of protection we are able to establish and maintain for
intellectual property rights covering our product candidates and
technology; (x) our ability to operate our business without infringing
the intellectual property rights and proprietary technology of third
parties; (xi) costs associated with defending intellectual property
infringement, product liability and other claims; (xii) regulatory
developments in the United States, Europe and other jurisdictions;
(xiii) estimates of our expenses, future revenues, capital requirements
and our needs for additional financing; (xiv) the potential benefits of
strategic collaboration agreements and our ability to enter into
strategic arrangements; (xv) our ability to maintain and establish
collaborations or obtain additional grant funding; (xvi) the rate and
degree of market acceptance of our product candidates; (xvii)
developments relating to our competitors and our industry, including
competing therapies; (xviii) our ability to effectively manage our
anticipated growth; (xix) our ability to attract and retain qualified
employees and key personnel; (xx) our ability to achieve cost savings
and other benefits from our efforts to streamline our operations and to
not harm our business with such efforts; (xxi) the use of proceeds from
our recent public offerings; (xxii) the potential benefits of any of our
product candidates being granted orphan drug designation; (xxiii) the
future trading price of the shares of our common stock and impact of
securities analysts’ reports on these prices; and/or (xxiv) other risks
and uncertainties. More detailed information about Kadmon and the risk
factors that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the U.S. Securities and Exchange
Commission (the “SEC”), including the Company’s Quarterly Report on Form
10-Q filed pursuant to Section 13 of the Securities Exchange Act of
1934, as amended, with the SEC on May 8, 2018. Investors and security
holders are urged to read these documents free of charge on the SEC’s
website at www.sec.gov.
The Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future events
or otherwise.


Investor Relations
Kadmon Holdings, Inc.
Ellen Tremaine,